254 related articles for article (PubMed ID: 25082741)
1. Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction.
Lok DJ; Klip IT; Voors AA; Lok SI; Bruggink-André de la Porte PW; Hillege HL; Jaarsma T; van Veldhuisen DJ; van der Meer P
Eur J Heart Fail; 2014 Sep; 16(9):958-66. PubMed ID: 25082741
[TBL] [Abstract][Full Text] [Related]
2. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
4. [Association of plasma amino-terminal pro-A-, B- and C-type natriuretic peptide levels with NYHA grade and echocardiographic derived parameters of cardiac function in heart failure patients].
Zhao XY; Yang YJ; Zhang J; Kang LM; Wei BQ; Gao XJ; Lü R; Zhang CL
Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Jun; 37(6):486-90. PubMed ID: 19927626
[TBL] [Abstract][Full Text] [Related]
5. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND.
Brouwers FP; de Boer RA; van der Harst P; Voors AA; Gansevoort RT; Bakker SJ; Hillege HL; van Veldhuisen DJ; van Gilst WH
Eur Heart J; 2013 May; 34(19):1424-31. PubMed ID: 23470495
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
7. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction.
van Veldhuisen DJ; Linssen GC; Jaarsma T; van Gilst WH; Hoes AW; Tijssen JG; Paulus WJ; Voors AA; Hillege HL
J Am Coll Cardiol; 2013 Apr; 61(14):1498-506. PubMed ID: 23500300
[TBL] [Abstract][Full Text] [Related]
8. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study.
Carlsen CM; Bay M; Kirk V; Gøtze JP; Køber L; Nielsen OW
Eur J Heart Fail; 2012 Mar; 14(3):240-7. PubMed ID: 22315457
[TBL] [Abstract][Full Text] [Related]
10. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
11. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction.
Izumiya Y; Hanatani S; Kimura Y; Takashio S; Yamamoto E; Kusaka H; Tokitsu T; Rokutanda T; Araki S; Tsujita K; Tanaka T; Yamamuro M; Kojima S; Tayama S; Kaikita K; Hokimoto S; Ogawa H
Can J Cardiol; 2014 Mar; 30(3):338-44. PubMed ID: 24484911
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions.
Bavishi C; Ather S; Bambhroliya A; Jneid H; Virani SS; Bozkurt B; Deswal A
Am J Cardiol; 2014 Jun; 113(11):1834-8. PubMed ID: 24837261
[TBL] [Abstract][Full Text] [Related]
13. Comparison of NT-proCNP and CNP plasma levels in heart failure, diabetes and cirrhosis patients.
Del Ry S; Cabiati M; Stefano T; Catapano G; Caselli C; Prescimone T; Passino C; Emdin M; Giannessi D
Regul Pept; 2011 Jan; 166(1-3):15-20. PubMed ID: 20800621
[TBL] [Abstract][Full Text] [Related]
14. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study.
Cleland JG; Taylor J; Freemantle N; Goode KM; Rigby AS; Tendera M
Eur J Heart Fail; 2012 May; 14(5):487-94. PubMed ID: 22505395
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction.
Koller L; Kleber M; Goliasch G; Sulzgruber P; Scharnagl H; Silbernagel G; Grammer T; Delgado G; Tomaschitz A; Pilz S; März W; Niessner A
Eur J Heart Fail; 2014 Jul; 16(7):758-66. PubMed ID: 24806206
[TBL] [Abstract][Full Text] [Related]
16. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 Study.
Takada T; Sakata Y; Miyata S; Takahashi J; Nochioka K; Miura M; Tadaki S; Shimokawa H;
Eur J Heart Fail; 2014 Mar; 16(3):309-16. PubMed ID: 24464774
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
[TBL] [Abstract][Full Text] [Related]
18. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study.
Voors AA; von Haehling S; Anker SD; Hillege HL; Struck J; Hartmann O; Bergmann A; Squire I; van Veldhuisen DJ; Dickstein K;
Eur Heart J; 2009 May; 30(10):1187-94. PubMed ID: 19346228
[TBL] [Abstract][Full Text] [Related]
19. Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction.
Maeder MT; Kaye DM
Int J Cardiol; 2012 Mar; 155(2):249-56. PubMed ID: 21035207
[TBL] [Abstract][Full Text] [Related]
20. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.
Senni M; Gavazzi A; Oliva F; Mortara A; Urso R; Pozzoli M; Metra M; Lucci D; Gonzini L; Cirrincione V; Montagna L; Di Lenarda A; Maggioni AP; Tavazzi L;
Int J Cardiol; 2014 May; 173(2):163-9. PubMed ID: 24630337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
